Most PAH patients who completed one year in a CS1 expanded access program had stable or improved clinical measures.

A study linked elevated blood levels of uric acid, a metabolic breakdown product often associated with gout, to a higher risk ...

Reflecting on this year's PHA conference in Dallas, columnist Mike Naple writes that connecting with community can be the ...

Nine members of the pulmonary hypertension (PH) community have received awards for their support of the Pulmonary ...

At the Pulmonary Hypertension Association’s (PHA) biannual conference, it is easy to feel like you should be able to do more. There are sessions to attend, people to meet, dinners to join, and ...

Blocking a signaling pathway in certain white blood cells may prevent blood clots from obstructing blood flow in the pulmonary arteries — the cause of chronic thromboembolic pulmonary hypertension ...

A gene called NDRG1 may help drive blood vessel remodeling seen in chronic thromboembolic pulmonary hypertension (CTEPH) by shifting smooth muscle cells toward a scar-forming state, a study found.

While both Winrevair (sotatercept) and prostacyclin therapies are used to treat pulmonary arterial hypertension (PAH), a new study shows the two treatments appear to affect blood flow differently ...

Enrollment is complete in the Phase 2 APEX trial of TX45, Tectonic Therapeutic‘s experimental drug for pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), ...

Low blood levels of several oxygen‐sensing molecules are found in people with pulmonary arterial hypertension (PAH), and testing for them may be a useful noninvasive tool for helping make a PAH ...